Fut, nem toboroz3. fázis
A clinical study of sotatercept in people with pulmonary arterial hypertension (MK-7962-038)
Key facts
- Where
- Angers, Brest, Grenoble Cedex 9, Le Kremlin Bicetre Cedex, Lille, Nice, Pessac, Poitiers, Saint-Herblain, Saint-Priest-en-Jarez, Strasbourg és Toulouse, FranciaországSee the 12 sites
- Phase
- 3. fázis
Where in Franciaország
- Centre Hospitalier Universitaire D'AngersAngers, FranciaországNo longer taking part
- Centre Hospitalier Régional et Universitaire de BrestBrest, FranciaországNo longer taking part
- Centre Hospitalier Universitaire Grenoble AlpesGrenoble Cedex 9, FranciaországNo longer taking part
- Bicetre HospitalLe Kremlin Bicetre Cedex, FranciaországNo longer taking part
- Centre Hospitalier Universitaire de LilleLille, FranciaországNo longer taking part
- Centre Hospitalier Universitaire de NiceNice, FranciaországNo longer taking part
- Centre Hospitalier Universitaire de BordeauxPessac, FranciaországNo longer taking part
- Centre Hospitalier Universitaire de PoitiersPoitiers, FranciaországNo longer taking part
- Centre Hospitalier Universitaire de NantesSaint-Herblain, FranciaországNo longer taking part
- Centre Hospitalier Universitaire de Saint EtienneSaint-Priest-en-Jarez, FranciaországNo longer taking part
- Les Hopitaux Universitaires de StrasbourgStrasbourg, FranciaországNo longer taking part
- Centre Hospitalier Universitaire de ToulouseToulouse, FranciaországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Merck Sharp & Dohme LLC
- Record updated
- 2026. november 6.
- Original description
To evaluate the long-term safety and tolerability of sotatercept.Read full original descriptionShow less
An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-038)
To evaluate the long-term safety and tolerability of sotatercept.
Inclusion: Has completed the MK-7962-004 study requirements; Is willing to adhere to the study visit schedule, and understands and will comply with all protocol requirements.
Exclusion: Is currently enrolled in another investigational product study other than a sotatercept study; Is or has an immediate family member who is investigational site or Sponsor staff directly involved with this study.